Elicio Therapeutics, Inc. financial data

Symbol
ELTX on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 218% % 3.7%
Debt-to-equity 3420% %
Return On Equity -5658% % -233%
Return On Assets -161% % 9.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 17,489,516 shares 62%
Common Stock, Shares, Outstanding 17,258,652 shares 60%
Entity Public Float $33,200,000 USD -30%
Common Stock, Value, Issued $173,000 USD 60%
Weighted Average Number of Shares Outstanding, Basic 16,692,476 shares 23%
Weighted Average Number of Shares Outstanding, Diluted 16,692,476 shares 23%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $30,532,000 USD 4.9%
General and Administrative Expense $11,817,000 USD 0.17%
Costs and Expenses $42,349,000 USD 3.5%
Operating Income (Loss) $42,349,000 USD -3.5%
Nonoperating Income (Expense) $3,508,000 USD 41%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $45,857,000 USD 2.1%
Earnings Per Share, Basic -3 USD/shares -117%
Earnings Per Share, Diluted -3 USD/shares -117%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $20,611,000 USD -21%
Assets, Current $21,465,000 USD -30%
Property, Plant and Equipment, Net $328,000 USD -37%
Operating Lease, Right-of-Use Asset $5,019,000 USD -15%
Assets $28,284,000 USD -26%
Accounts Payable, Current $321,000 USD -84%
Employee-related Liabilities, Current $1,688,000 USD 15%
Accrued Liabilities, Current $5,213,000 USD 7.4%
Contract with Customer, Liability, Current $0 USD -100%
Liabilities, Current $6,515,000 USD -28%
Operating Lease, Liability, Noncurrent $4,356,000 USD -18%
Liabilities $24,468,000 USD -57%
Accumulated Other Comprehensive Income (Loss), Net of Tax $31,000 USD 85%
Retained Earnings (Accumulated Deficit) $225,954,000 USD -25%
Stockholders' Equity Attributable to Parent $3,816,000 USD
Liabilities and Equity $28,284,000 USD -26%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $10,119,000 USD 17%
Net Cash Provided by (Used in) Financing Activities $10,328,000 USD -6.3%
Net Cash Provided by (Used in) Investing Activities $0 USD -100%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 17,273,107 shares 60%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $240,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $21,313,000 USD -24%
Deferred Tax Assets, Valuation Allowance $100,117,000 USD 11%
Operating Lease, Liability $5,337,000 USD -14%
Depreciation $392,000 USD
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $45,686,000 USD 2.8%
Lessee, Operating Lease, Liability, to be Paid $6,378,000 USD -17%
Property, Plant and Equipment, Gross $2,035,000 USD 2.3%
Operating Lease, Liability, Current $981,000 USD 12%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,425,000 USD 3%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,383,000 USD 2.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,041,000 USD -31%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,467,000 USD 2.9%
Deferred Tax Assets, Operating Loss Carryforwards $64,646,000 USD 6.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $4,100,000 USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,512,000 USD 3.1%
Operating Lease, Payments $334,000 USD -12%
Additional Paid in Capital $229,778,000 USD 42%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $2,389,000 USD 80%
Interest Expense $753,000 USD -89%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%